Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;38(7):1767-1775.
doi: 10.1007/s10815-021-02168-3. Epub 2021 Apr 1.

Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: a retrospective study of ten years of experience

Anne Mayeur  1 , Vincent Puy  2   3 , Victoria Windal  2 , Laetitia Hesters  2 , Vanessa Gallot  4 , Alexandra Benoit  4 , Michael Grynberg  4 , Charlotte Sonigo #  4 , Nelly Frydman #  2   3
Affiliations

Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: a retrospective study of ten years of experience

Anne Mayeur et al. J Assist Reprod Genet. 2021 Jul.

Abstract

Purpose: The aim of this study was to evaluate the outcomes of frozen oocytes or embryos cryopreserved after controlled ovarian stimulation (COS) or in vitro maturation (IVM) for female cancer patients who underwent a fertility preservation (FP) prior to gonadotoxic therapy.

Methods: A retrospective cohort study from 2009 to December 2017 was conducted. Among the 667 female cancer patients who underwent oocytes or embryos cryopreservation for FP, 40 (6%) have returned to the fertility clinic between 2011 and 2019 to use their frozen material after being cured. We compared these thaw cycles outcomes according to the techniques used at the time of cryopreservation.

Results: Among the 40 women cancer survivors who used their cryopreserved material, thirty patients have benefited from at least one embryo transfer. Ten patients did not have an embryo transfer since the oocytes did not survive after the thawing process or because no embryo was obtained after fertilization. We related three live births following FP using IVM (two from frozen oocytes and one after embryo cryopreservation). Five live births were obtained when COS was performed at the time of FP (one from frozen oocytes and four after embryo cryopreservation).

Conclusions: Our preliminary results, although they are obtained in a small sample, are encouraging and show that different FP techniques can be used in female cancer patients and lead to live births. IVM is one of the options available that does not delay the start of chemotherapy or if ovarian stimulation using gonadotropins is contraindicated.

Keywords: In vitro maturation; Live birth; Oncofertility preservation; Oocyte cryopreservation; Zygote cryopreservation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the study; 667 female patients underwent our FP program before a gonadotoxic treatment from January 2009 to October 2017. Forty patients cured from cancer asked for the use of oocytes or embryos cryopreserved in this context. We divided this population into four groups according to FP technique performed: oocyte or zygote cryopreservation after COS (OO-COS and ZYG-COS) or after IVM (OO-IVM and ZYG-IVM). COS, controlled ovarian stimulation; IVM, in vitro maturation; OO-COS, oocytes cryopreserved after controlled ovarian stimulation; OO-IVM, oocytes cryopreserved after in vitro maturation; ZYG-COS, zygotes cryopreserved after controlled ovarian stimulation; ZYG-IVM, zygotes cryopreserved after in vitro maturation
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff AS, Bossard N. Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012 : étude à partir des registres des cancers du réseau Francim. Partie 1 - Tumeurs solides [Internet]. Institut de veille sanitaire; 2013 [cited 2020 Sep 26]. Available from: https://hal.archives-ouvertes.fr/hal-02084700
    1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. - DOI - PubMed
    1. Donnez J, Dolmans M-M. Fertility preservation in women. Nat Rev Endocrinol. 2013;9:735–749. doi: 10.1038/nrendo.2013.205. - DOI - PubMed
    1. Reh AE, Lu L, Weinerman R, Grifo J, Krey L, Noyes N. Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: results of a registry of female cancer patients at 2 years. J Assist Reprod Genet. 2011;28:635–641. doi: 10.1007/s10815-011-9559-z. - DOI - PMC - PubMed

LinkOut - more resources